SPRY Insider Trading

Insider Ownership Percentage: 40.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $38,255,298.78

ARS Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at ARS Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$615ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M$0$20MTotal Insider BuyingTotal Insider Selling

ARS Pharmaceuticals Share Price & Price History

Current Price: $14.88
Price Change: +0.30 (1.20%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for SPRY up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$14.88Closing price on 04/19/25:

SEC Filings (Institutional Ownership Changes) for ARS Pharmaceuticals (NASDAQ:SPRY)

68.16% of ARS Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SPRY by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$6.39Mbought$220ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100M$0$100MTotal InflowsTotal Outflows
ARS Pharmaceuticals logo
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Read More on ARS Pharmaceuticals

Today's Range

Now: $14.88
Low: $14.43
High: $15.09

50 Day Range

MA: $12.27
Low: $10.18
High: $14.99

52 Week Range

Now: $14.88
Low: $7.55
High: $18.51

Volume

1,550,196 shs

Average Volume

1,155,748 shs

Market Capitalization

$1.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Who are the company insiders with the largest holdings of ARS Pharmaceuticals?

ARS Pharmaceuticals' top insider shareholders include:
  1. Ra Capital Management, LP (Director)
  2. James E Flynn (Major Shareholder)
  3. Sarina Tanimoto (Insider)
  4. Richard E Lowenthal (CEO)
  5. Peter A Thompson (Director)
  6. Laura Shawver (Director)
  7. Justin Chakma (Insider)
  8. Alexander A Fitzpatrick (Insider)
  9. Kathleen D Scott (CFO)
  10. Eric Karas (Insider)
  11. Brian Dorsey (COO)
Learn More about top insider investors at ARS Pharmaceuticals.

Who are the major institutional investors of ARS Pharmaceuticals?

ARS Pharmaceuticals' top institutional shareholders include:
  1. Janney Montgomery Scott LLC — 0.46%
  2. Rhumbline Advisers — 0.07%
  3. SG Americas Securities LLC — 0.04%
  4. GAMMA Investing LLC — 0.00%
Learn More about top institutional investors of ARS Pharmaceuticals stock.

Which major investors are selling ARS Pharmaceuticals stock?

In the last quarter, SPRY stock was sold by these institutional investors:
  1. SG Americas Securities LLC
In the last year, company insiders that have sold ARS Pharmaceuticals company stock include:
  1. Ra Capital Management, LP (Director)
  2. James E Flynn (Major Shareholder)
  3. Sarina Tanimoto (Insider)
  4. Richard E Lowenthal (CEO)
  5. Peter A Thompson (Director)
  6. Laura Shawver (Director)
  7. Justin Chakma (Insider)
  8. Alexander A Fitzpatrick (Insider)
  9. Kathleen D Scott (CFO)
Learn More investors selling ARS Pharmaceuticals stock.

Which major investors are buying ARS Pharmaceuticals stock?

During the last quarter, SPRY stock was purchased by institutional investors including:
  1. Janney Montgomery Scott LLC
  2. Rhumbline Advisers
  3. GAMMA Investing LLC
During the last year, these company insiders have bought ARS Pharmaceuticals stock:
  1. Ra Capital Management, LP (Director)
  2. James E Flynn (Major Shareholder)
Learn More investors buying ARS Pharmaceuticals stock.